Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Glioblastoma × Flucytosine × Clear all

Phase

Phase 1 7 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Glioblastoma 1 Astrocytoma 1

Interventions

Temozolomide 8 Lomustine 4 vocimagene amiretrorepvec 2 Radiation 2 veliparib 1 regorafenib 1 carbon-11 acetate 1 antisecretory factor 1 Sunitinib 1 Standard of Care 1 Radiotherapy 1 Magnetic Resonance Spectroscopy 1 Irinotecan 1 GDC-0084 1 Flucytosine 1 Etoposide 1 Drug Therapy 1 Disulfiram 1 Dianhydrogalactitol 1 DNA 1 Copper 1 Carbon-11 1 Bevacizumab 1 Alkylating Agents 1 AZD1390 1 ADI PEG20 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02414165 2020-02-07

Toca5

Tocagen Inc.

Phase 2/3 Terminated

Astrocytoma, Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡